Bristol-Myers Squibb To Present New Data For Opdivo (nivolumab) in Advanced Melanoma, As Monotherapy And In Combination With Yervoy (ipilimumab), At The Society For Melanoma Research 2015 International Congress

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced results of new clinical research of its Immuno-Oncology agents – Opdivo and Yervoy – will be presented at the Society for Melanoma Research (SMR) 2015 International Congress in San Francisco, CA from November 18 – 21. Studies to be presented at SMR illustrate Bristol-Myers Squibb’s scientific commitment, through its Immuno-Oncology research, to developing treatment options for patients with advanced melanoma.

Help employers find you! Check out all the jobs and post your resume.